Merck's Clesrovimab Shows Promise in Reducing RSV in Infants, Poised for Approval by 2025-26
Merck's clesrovimab has shown impressive results in reducing RSV-related illnesses and hospitalizations in infants during its Phase 2b/3 trial, with the data indicating a 60% reduction in RSV infections and up to a 91% decrease in RSV-associated hospitalizations compared to placebo[1][3]. Tested in over 3,600 healthy preterm and full-term infants, clesrovimab met its primary endpoints without any serious adverse events linked to the drug[1][2]. These promising results highlight its potential as a first-line immunization option for infants during their first RSV season, pending expected approval for the 2025-26 season[2][3].
References
- Merck antibody reduces RSV-related disease, hospitalizations in trial
- Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
- With trial win, Merck's RSV antibody clesrovimab looks poised to take on Sanofi and AZ's Beyfortus
Explore Further
What are the main differences between Merck's clesrovimab and its competitor Beyfortus in terms of efficacy and safety?
How does the reduction in RSV infections and hospitalizations by clesrovimab compare to current treatments for RSV in infants?
What challenges might Merck face in gaining approval for clesrovimab by the 2025-26 RSV season?
How might clesrovimab's introduction to the market impact the existing treatments for RSV in infants?
What are the financial implications for Merck if clesrovimab successfully enters the RSV prevention market by 2025-26?